GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States ...

The College of Nurses of Ontario (CNO) welcomes the Ontario government's new bill to promote labour mobility in Canada, so we can continue to enable more nurses to provide safe ...

Stroke is the fourth leading cause of death among Hispanic men and the third leading cause for Hispanic women in the United States. Yet, according to CDC reports, only 58% of Hispanic adults can ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 ...

In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer, where it splits the market evenly with Merck’s pembrolizumab.

In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer, where it splits the market evenly with Merck’s pembrolizumab.

Immunotherapy drugs approved for advanced endometrial cancer include: Dostarlimab (Jemperli) Durvalumab (Imfinzi) Pembrolizumab (Keytruda) Combined with chemotherapy, treatment with immune ...